domain, wherein one of said first and second polypeptide chains contains said positively charged polypeptide domain that spontaneously assumes a helical conformation and the other of said first and second polypeptide chains contains said negatively charged polypeptide domain that spontaneously assumes a helical conformation.

Claim 3. The diabody molecule of claim 1 or 2, wherein said first polypeptide chain additionally comprises a third domain, said third domain being separated from said second domain by said charged polypeptide domain, wherein said third domain is an Fc domain, a heavy chain constant region 2 (CH2) and/or a heavy chain constant region 3 (CH3) domain.

Claim 4. The diabody molecule of any one of claims 1-3, wherein said second polypeptide chain additionally comprises a sixth domain, said sixth domain being separated from said fifth domain by said charged polypeptide domain, wherein said sixth domain is an Fc domain, a heavy chain constant region 2 (CH2) and/or a heavy chain constant region 3 (CH3) domain.

Claim 5. The diabody molecule of any one of claims 1-3, wherein said diabody additionally comprises a third polypeptide chain and a fourth polypeptide chain, said third and fourth polypeptide chains being covalently bonded to one another, wherein:

III. said third polypeptide chain comprises, in the N-terminal to C-terminal direction: (i) a seventh domain comprising a binding region of a light chain variable domain of a third immunoglobulin (VL3) specific for an epitope (3), (ii) an eighth domain comprising a binding region of a heavy chain variable domain of a fourth immunoglobulin (VH4) specific for an epitope (4), (iii) a positively or negatively charged polypeptide domain that spontaneously assumes a helical conformation, and (iv) a ninth domain, wherein said ninth domain is an Fc domain, a heavy chain constant region 2 (CH2) and/or a heavy chain constant region 3 (CH3) domain;

which seventh domain and eighth domain are covalently linked such that the seventh domain and eighth domain do not associate together to form said epitope (3) binding site or said epitope (4) binding site;

Claim 9. The diabody molecule of claim 1 or 2, wherein said first polypeptide chain additionally comprises a polypeptide portion of a protein that binds to a serum protein, said polypeptide portion being capable of binding to said serum protein.

Claim 10. The diabody molecule of claim 9, wherein said second polypeptide chain additionally comprises a polypeptide portion of a protein that binds to a serum protein, said polypeptide portion being capable of binding to said serum protein.

Claim 11. The diabody molecule of claim 9 or 10, wherein said protein that binds to a serum protein is an albumin binding protein.

Claim 12. The diabody molecule of claim 11, wherein said albumin binding protein is streptococcal protein G and said polypeptide portion is an albumin-binding domain (ABD) of said streptococcal protein G.

Claim 13. The diabody molecule of claim 12, wherein said albumin-binding domain (ABD) of said streptococcal protein G is albumin-binding domain 3 (ABD3) of protein G of Streptococcus strain G148.

Claim 14. The diabody molecule of any one of claims 9-13, wherein said diabody molecule exhibits an in vivo serum half-life of greater than 2 hours.

Claim 15. The diabody molecule of claim 14, wherein said diabody molecule exhibits an in vivo serum half-life of greater than 10 hours.

Claim 16. The diabody molecule of claim 15, wherein said diabody exhibits an in vivo serum half-life greater than 20 hours.

Claim 17. The diabody molecule of any one of claims 1-15, wherein said diabody molecule binds an epitope of CD32B and an epitope of CD16.

Claim 18. The diabody molecule of any of claims 1-15, wherein said diabody molecule binds to the Natural Killer Group 2D (NKG2D) receptor.

Claim 19. The diabody molecule of any one of claims 1-15, wherein said diabody molecule binds to the T-cell receptor (TCR).

Claim 20. The diabody molecule of any one of claims 1-19, wherein said diabody molecule binds to a tumor-associated antigen.

Claim 21. The diabody molecule of claim 20, wherein said tumor-associated antigen is a breast cancer antigen, an ovarian cancer antigen, a prostate cancer antigen, a cervical cancer antigen, a pancreatic carcinoma antigen, a lung cancer antigen, a bladder cancer antigen, a colon cancer antigen, a testicular cancer antigen, a glioblastoma cancer antigen, an antigen associated with a B cell malignancy, an antigen associated with multiple myeloma, an antigen associated with non-Hodgkin's lymphoma, or an antigen associated with chronic lymphocytic leukemia.

Claim 22. The diabody molecule of claim 20, wherein said tumor-associated antigen is A33; ADAM-9; ALCAM; B1; BAGE; beta-catenin; CA125; Carboxypeptidase M; CD5; CD19; CD20; CD22; CD23; CD25; CD27; CD28; CD32B; CD36; CD40; CD45; CD46; CD56; CD79a; CD79b; CD103; CD154; CDK4; CEA; CTLA4; Cytokeratin 8; EGF-R; an Ephrin receptor; ErbB1; ErbB3; ErbB4; GAGE-1; GAGE-2; GD2; GD3; GM2; gp100; HER-2/neu; human papillomavirus-E6; human papillomavirus-E7; Integrin Alpha-V-Beta-6; JAM-3; KID3; KID31; KSA; LUCA-2; MAGE-1; MAGE-3; MART; MUC-1; MUM-1; N-acetylglucosaminyltransferase; Oncostatin M; p15; PIPA; PSA; PSMA; RAAG10; ROR1; SART; sTn; TES7; the TNF-α receptor; the TNF-ß receptor; the TNF-γ receptor; the Transferrin Receptor or the VEGF receptor.

Claim 23. The diabody molecule of claim 22, wherein said tumor-associated antigen is HER-2/neu.

Claim 24. A diabody molecule comprising a first polypeptide chain and a second polypeptide chain, wherein said first polypeptide chain and said second

polypeptide chain are covalently linked to one another, with the proviso that the covalent link is not a peptide bond, wherein:

said first polypeptide chain comprises: (i) a first domain comprising a binding region of a light chain variable domain of a first immunoglobulin (VL1) specific for CD32B, (ii) a second domain comprising a binding region of a heavy chain variable domain of a second immunoglobulin (VH2) specific for CD79b, and (iii) a third domain comprising at least one cysteine residue, and an E-coil separator (SEQ ID NO:299) or a K-coil separator (SEQ ID NO:300), which first domain and second domain are covalently linked such that the first domain and second domain do not associate to form a first epitope binding site;

said second polypeptide chain comprises: (i) a fourth domain comprising a binding region of a light chain variable domain of the second immunoglobulin (VL2) specific for CD79b, (ii) a fifth domain comprising a binding region of a heavy chain variable domain of the first immunoglobulin (VH1) specific for CD32B, and (iii) a sixth domain comprising at least one cysteine residue, and an E-coil separator (SEQ ID NO:299) or a K-coil separator (SEQ ID NO:300), which fourth domain and fifth domain are covalently linked such that the fourth domain and fifth domain do not associate to form an epitope binding site;

wherein said cysteine residue of said third and sixth domains form a disulfide bond between said first and second polypeptide chains;

wherein when said first polypeptide chain comprises said E-coil separator, said second polypeptide chain comprises said K-coil separator; and when said first polypeptide chain comprises said K-coil separator, said second polypeptide chain comprises said E-coil separator;

wherein the first domain and the fifth domain associate to form a first binding site (VL1)(VH1) that binds CD32B;

wherein the second domain and the fourth domain associate to form a second binding site (VL2)(VH2) that binds CD79b.

Claim 25. The diabody molecule of claim 24, wherein said first polypeptide chain or said second polypeptide chain further comprises an Fc domain, a heavy chain constant region 2 (CH2) and/or a heavy chain constant region 3 (CH3) domain.

Claim 26. The diabody molecule of claim 25, wherein said Fc domain, said CH2 and/or said CH3 is linked to said E-coil separator or said K-coil separator.

Claim 27. The diabody molecule of claim 25, wherein said Fc domain, said CH2 and/or said CH3 is linked to the N-terminus of said first domain or said fourth domain.

Claim 28. A diabody that is a dimer of two diabody molecules, wherein:

(A) the first of said two diabody molecules comprises a first polypeptide chain and a second polypeptide chain, wherein said first polypeptide chain and said second polypeptide chain of said first diabody molecule are covalently linked to one another, with the proviso that the covalent link is not a peptide bond, and wherein:

said first polypeptide chain of said first diabody molecule comprises: (i) a first domain comprising a binding region of a light chain variable domain of a first immunoglobulin (VL1) specific for CD32B, (ii) a second domain comprising a binding region of a heavy chain variable domain of a second immunoglobulin (VH2) specific for CD79b, and (iii) a third domain comprising at least one cysteine residue, an E-coil separator (SEQ ID NO:299) or a K-coil separator (SEQ ID NO:300), and a CH2 domain and a CH3 domain; which first domain and second domain are covalently linked such that the first domain and second domain do not associate to form a first epitope binding site;

said second polypeptide chain of said first diabody molecule comprises: (i) a fourth domain comprising a binding region of a light chain variable domain of the second immunoglobulin (VL2) specific for CD79b, (ii) a fifth domain comprising a binding region of a heavy chain variable domain of the first immunoglobulin (VH1) specific for CD32B, and (iii) a sixth domain comprising at least one cysteine residue, and an E-coil separator (SEQ ID NO:299) or a K-coil separator (SEQ ID NO:300), which fourth domain and fifth domain are covalently linked such that the fourth domain and fifth domain do not associate to form an epitope binding site;

wherein when said first polypeptide chain of said first diabody comprises said E-oil separator, said second polypeptide chain of said first diabody comprises said K-coil separator; and when said first polypeptide chain of said first diabody

cysteine residue, an E-coil separator (SEQ ID NO:299) or a K-coil separator (SEQ ID NO:300), and a CH2 domain and a CH3 domain; which first domain and second domain are covalently linked such that the first domain and second domain do not associate to form a first epitope binding site;

said second polypeptide chain of said second diabody molecule comprises: (i) a fourth domain comprising a binding region of a light chain variable domain of the second immunoglobulin (VL2) specific for CD32B, (ii) a fifth domain comprising a binding region of a heavy chain variable domain of the first immunoglobulin (VH1) specific for CD79b, and (iii) a sixth domain comprising at least one cysteine residue, and an E-coil separator (SEQ ID NO:299) or a K-coil separator (SEQ ID NO:300), which fourth domain and fifth domain are covalently linked such that the fourth domain and fifth domain do not associate to form an epitope binding site;

wherein when said first polypeptide chain of said second diabody comprises said E-coil separator, said second polypeptide chain of said second diabody comprises said K-coil separator; and when said first polypeptide chain of said second diabody comprises said K-coil separator, said second polypeptide chain of said second diabody comprises said E-coil separator;

wherein said cysteine residue of said third and sixth domains of said second diabody molecule form a disulfide bond between said first and second polypeptide chains of said second diabody molecule;

wherein the first domain and the fifth domain of said second diabody molecule associate to form a first binding site (VL1)(VH1) that binds CD79b;

wherein the second domain and the fourth domain of said second diabody molecule associate to form a second binding site (VL2)(VH2) that binds CD32B;

wherein said CH2 domain and CH3 domain of said first polypeptide chain of said first diabody associates with said CH2 domain and CH3 domain of said first polypeptide chain of said second diabody molecules to form an Fc region.

Claim 30. The diabody molecule of claim 24, wherein both said E-coil separator and said K-coil separator are linked to an Fc domain, a heavy chain constant region 2 (CH2) and/or a heavy chain constant region 3 (CH3) domain.

Claim 39. The diabody molecule of claim 38, wherein said second polypeptide chain comprises said light chain variable domain, said intervening GGGSGGGG linker (SEQ ID NO:10) and said heavy chain variable domain of SEQ ID NO:254.

Claim 40. The diabody molecule of claim 38, wherein said second polypeptide chain comprises said light chain variable domain, said intervening GGGSGGGG linker (SEQ ID NO:10) and said heavy chain variable domain of SEQ ID NO:256.

Claim 41. The diabody molecule of claim 29, wherein:

(A) said first polypeptide chain comprises:

(i) the light chain variable domain, the intervening GGGSGGGG linker (SEQ ID NO:10) and the heavy chain variable domain of SEQ ID NO:254; or

(ii) the light chain variable domain, the intervening GGGSGGGG linker (SEQ ID NO:10) and the heavy chain variable domain of SEQ ID NO:256; and

(B) said second polypeptide chain comprises the light chain variable domain, the intervening GGGSGGGG linker (SEQ ID NO:10) and the heavy chain variable domain of SEQ ID NO:252.

Claim 42. The diabody molecule of claim 41, wherein said first polypeptide chain comprises said light chain variable domain, said intervening GGGSGGGG linker (SEQ ID NO:10) and said heavy chain variable domain of SEQ ID NO:254.

Claim 43. The diabody molecule of claim 42, wherein said first polypeptide chain comprises said light chain variable domain, said intervening GGGSGGGG linker (SEQ ID NO:10) and said heavy chain variable domain of SEQ ID NO:256.

Claim 44. A pharmaceutical composition comprising the diabody molecule of any one of claims 1-43 and a pharmaceutically acceptable carrier.

Claim 45. Use of the diabody molecule of any one of claims 24-43 or the pharmaceutical composition of claim 44 for the manufacture of a medicament for inhibiting B-cell proliferation.